Advertisement

Topics

PubMed Journals Articles About "Screening Reduces Prostate Cancer Deaths" RSS

13:27 EDT 23rd March 2019 | BioPortfolio

Screening Reduces Prostate Cancer Deaths PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Screening Reduces Prostate Cancer Deaths articles that have been published worldwide.

More Information about "Screening Reduces Prostate Cancer Deaths" on BioPortfolio

We have published hundreds of Screening Reduces Prostate Cancer Deaths news stories on BioPortfolio along with dozens of Screening Reduces Prostate Cancer Deaths Clinical Trials and PubMed Articles about Screening Reduces Prostate Cancer Deaths for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Screening Reduces Prostate Cancer Deaths Companies in our database. You can also find out about relevant Screening Reduces Prostate Cancer Deaths Drugs and Medications on this site too.

Showing "screening reduces prostate cancer deaths" PubMed Articles 1–25 of 22,000+

PSA screening and molecular markers.

Prostate cancer (PCA) is the most common type of cancer in men. The significant increase in incidence is most likely caused by the overdiagnosis of prostate cancer by widespread prostate-specific antigen (PSA) screening.


Twitter Response to the 2018 United States Preventive Services Task Force Guidelines on Prostate Cancer Screening.

Prostate cancer screening reduces advanced disease and prostate cancer death but is controversial due to downstream harms including unnecessary biopsies and overtreatment. In 2012 the United States Preventive Services Task Force (USPSTF) recommended against screening men for prostate cancer, a practice common since the early 1990's. This dramatic policy change was opposed by many physicians and patient groups. Our group reported on the Twitter response within 24 hours of these guidelines, showing a missed o...

Limitations in the Effect of Screening on Breast Cancer Mortality.

Purpose Randomized, controlled trials showed that screening reduces breast cancer mortality rates, but some recent observational studies have concluded that programmatic screening has had minor effect on breast cancer mortality rates. This apparent contradiction might be explained by the use of aggregated data in observational studies. We assessed the long-term effect of screening using individual-level data. Materials and Methods Using data from mammography screening in the Copenhagen and Danish national r...


Association between Trichomonas vaginalis and prostate cancer mortality.

We previously observed a positive association between seropositivity for the parasite Trichomonas vaginalis and risk of clinically significant prostate cancer at diagnosis. Here, we examined whether T. vaginalis seropositivity was associated with increased prostate cancer-specific or all-cause mortality among prostate cancer patients. We studied 749 men with prostate cancer from the Physicians' Health Study (PHS) and 736 men with prostate cancer from the Health Professionals Follow-Up Study (HPFS). We used ...

Modifiable Failures in the Colorectal Cancer Screening Process and Their Association with Risk of Death.

Colorectal cancer (CRC) deaths occur when patients do not receive screening or have inadequate follow up of abnormal results, or when the screening test itself fails. We have few data on the contribution of each to CRC-associated deaths or factors associated with these events.

Vitamin K intake and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial.

Vitamin K inhibits prostate cancer cells, and an altered expression of vitamin K-dependent proteins in prostate tumors has been linked to their aggressiveness and progression. However, little is known about the effect of vitamin K intake on prostate cancer in human populations.

A paradigm shift for prostate cancer diagnostics.

The current praxis of diagnosing prostate cancer, with systematic prostate biopsies in men with raised serum prostate-specific antigen (PSA) levels, leads to considerable over-diagnosis and over-treatment of indolent cancer. Recent research has opened up for a paradigm shift to risk stratified, sequential and targeted prostate cancer diagnostics, which will reduce over-diagnosis. Sweden now moves towards organised PSA testing for those men who, after proper counselling, wish to be tested. Organised PSA test...

Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines.

Prostate cancer is the third leading cause of cancer-related death in men in the United States. Although serious, most of these diagnoses are not terminal. Inherited risk for prostate cancer is associated with aggressive disease and poorer outcomes, indicating a critical need for increased genetic screening to identify disease-causing variants that can pinpoint individuals at increased risk for metastatic castration-resistant prostate cancer.

Intake of Individual Fatty Acids and Risk of Prostate Cancer in the European Prospective Investigation into Cancer and Nutrition.

The associations of individual dietary fatty acids with prostate cancer risk have not been examined comprehensively. We examined the prospective association of individual dietary fatty acids with prostate cancer risk overall, by tumor subtypes, and prostate cancer death. 142,239 men from the European Prospective Investigation into Cancer and Nutrition who were free from cancer at recruitment were included. Dietary intakes of individual fatty acids were estimated using center-specific validated dietary quest...

Energy Dispersive X-Ray Fluorescence Zn/Fe Ratiometric Determination of Zinc Levels in Expressed Prostatic Fluid: A Direct, Non-Invasive and Highly Accurate Screening for Prostate Cancer.

Prostate specific antigen (PSA) does not provide the reliability that is required for the accurate urology screening of prostate cancer (PCa). Consequently, there has been a major focus and search for a simple, rapid, direct, preferably non-invasive, and highly accurate biomarker and procedure for the urology screening for prostate cancer. Virtually all PCa cases exhibit a marked decrease in zinc in prostate tissue and in prostatic fluid. This is a hallmark "signature" clinical characteristic for all prosta...

Causes of death in men with prostate cancer: Results from the Danish Prostate Cancer Registry (DAPROCAdata).

Current knowledge of the validity of registry data on prostate cancer-specific death is limited. We aimed to determine the underlying cause of death among Danish men with prostate cancer, to estimate the level of misattribution of prostate cancer death, and to examine the risk of death from prostate cancer when accounting for competing risk of death.

A natural history model for planning prostate cancer testing: Calibration and validation using Swedish registry data.

Recent prostate cancer screening trials have given conflicting results and it is unclear how to reduce prostate cancer mortality while minimising overdiagnosis and overtreatment. Prostate cancer testing is a partially observable process, and planning for testing requires either extrapolation from randomised controlled trials or, more flexibly, modelling of the cancer natural history. An existing US prostate cancer natural history model (Gulati et al, Biostatistics 2010;11:707-719) did not model for differen...

Recent incidence and surgery trends for prostate cancer: Towards an attenuation of overdiagnosis and overtreatment?

Screening for prostate cancer is frequent in high-income countries, including Switzerland. Notably due to overdiagnosis and overtreatment, various organisations have recently recommended against routine screening, potentially having an impact on incidence, mortality, and surgery rates. Our aim was therefore to examine whether secular trends in the incidence and mortality of prostate cancer, and in prostatectomy rates, have recently changed in Switzerland.

The association between medicare accountable care organization enrollment and breast, colorectal, and prostate cancer screening.

Despite the rapid diffusion of accountable care organizations (ACOs), the effect of ACO enrollment on cancer diagnosis, treatment, and survivorship remains unknown. The objective of this study was to determine whether Medicare Shared Savings Program (MSSP) ACO enrollment was associated with changes in screening for breast, colorectal, and prostate cancers.

Imaging the Human Prostate Gland Using 1-μm-Resolution Optical Coherence Tomography.

The accuracy of needle biopsy for the detection of prostate cancer is limited by well-known sampling errors. Thus, there is an unmet need for a microscopic screening tool that can screen large regions of the prostate comprehensively for cancer. Previous prostate imaging by optical coherence tomography (OCT) have had insufficient resolution for imaging cellular features related to prostate cancer. We have recently developed micro-optical coherence tomography (μOCT) that generates depth-resolved tissue image...

Genetic profiling in the diagnosis of hereditary prostate cancer: Where do we stand?

Prostate cancer has a heterogeneous genetic profile compared with other tumour entities. Accordingly, there are also various mutations that increase the risk of prostate cancer. Some genetic variants only have a mild impact, whereas other gene mutations (BRCA1 /2; HOXB13) may increase the risk significantly. All in all, a man with a negative family history is unlikely to be a carrier of mutations that are associated with an increased risk of PCa. However, this likelihood increases if the family history is...

Guideline: Experts recommend against prostate cancer screening with prostate-specific antigen test.

Personalized Prostate Cancer Screening Based on a Single Midlife Prostate-specific Antigen Measurement.

Establishing Baseline Cervical Cancer Screening Coverage - India, 2015-2016.

Cervical cancer is the second leading cause of new cancer cases and cancer-related deaths among women in India, with an estimated 96,922 new cases and 60,078 deaths each year.* Despite the availability of effective low-cost screening options in India, limited access to screening and treatment services, diagnosis at a later stage, and low investment in health care infrastructure all contribute to the high number of deaths (1). In 2016 the Ministry of Health and Family Welfare of India recommended cervical ca...

Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer.

We report herein the discovery of highly potent PROTAC degraders of androgen receptor (AR), as exemplified by compound 34 (ARD-69). ARD-69 induces degradation of AR protein in AR-positive prostate cancer cell lines in a dose- and time-dependent manner. ARD-69 achieves DC values of 0.86, 0.76, and 10.4 nM in LNCaP, VCaP, and 22Rv1 AR+ prostate cancer cell lines, respectively. ARD-69 is capable of reducing the AR protein level by >95% in these prostate cancer cell lines and effectively suppressing AR-regulate...

Surgical treatment of prostate cancer.

Prostate cancer is one of the most commonly diagnosed malignant neoplasms. In Hungary, 4000-4500 men are diagnosed annually, which is below the European incidence. In contrast, the Hungarian prostate cancer mortality clearly exceeds the EU average. This is probably due to the lack of awareness and early recognition of prostate cancer. At an early stage, prostate cancer can be cured, 5-year survival is almost 100%, while in metastatic form it is only 28%. There are several treatment options available for pro...

Inhibition of tankyrase by a novel small molecule significantly attenuates prostate cancer cell proliferation.

Tankyrase (TNKS) is a crucial mediator of Wnt signal transduction and has been recognized as a novel molecular target for Wnt-pathway dependent cancer. TNKS is stabilized by the ubiquitin-specific protease 25 (USP25). The effect of disruption of the interaction between TNKS and USP25 by small molecules on prostate cancer proliferation is unknown. In this study we conducted a hierarchical virtual screening with more than 200,000 compounds on the characterized structures of the USP25/TNKS-ARC5 protein complex...

Cannabinoid WIN 55,212-2 induces cell cycle arrest and apoptosis, and inhibits proliferation, migration, invasion, and tumor growth in prostate cancer in a cannabinoid-receptor 2 dependent manner.

Cannabinoids have demonstrated anticarcinogenic properties in a variety of malignancies, including in prostate cancer. In the present study, we explored the anti-cancer effects of the synthetic cannabinoid WIN 55,212-2 (WIN) in prostate cancer.

Prostate Cancer Mortality rates in Peru and its geographic regions.

Prostate cancer is the fifth most prevalent cause of cancer death in men worldwide. A recent report described the mortality rates for prostate cancer in Peru, but a comprehensive evaluation of variations in prostate cancer epidemiology by geographic areas has not been performed, yet. Our aim is to evaluate the mortality rates of prostate cancer, according to geographical areas in Peru, between 2005 and 2014.

Immunotherapy for the treatment of prostate cancer-a comeback?

Prostate cancer (PCA) seems to be more of an immunologic desert than other tumor entities. It is striking that only rarely does prostate cancer show abundant immune cells and a proimmunogenic microenvironment.


Advertisement
Quick Search
Advertisement
Advertisement